0000899243-20-031479.txt : 20201118
0000899243-20-031479.hdr.sgml : 20201118
20201118184656
ACCESSION NUMBER: 0000899243-20-031479
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201118
FILED AS OF DATE: 20201118
DATE AS OF CHANGE: 20201118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
CENTRAL INDEX KEY: 0001787092
STATE OF INCORPORATION: E9
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39712
FILM NUMBER: 201326515
BUSINESS ADDRESS:
STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC
STREET 2: 280 CONGRESS STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: (617) 951-5372
MAIL ADDRESS:
STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC
STREET 2: 280 CONGRESS STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Olema Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001750284
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 300409740
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 512 2ND STREET, 4TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
BUSINESS PHONE: (415) 651-3316
MAIL ADDRESS:
STREET 1: 512 2ND STREET, 4TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-11-18
0
0001750284
Olema Pharmaceuticals, Inc.
OLMA
0001787092
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
C/O WELLINGTON MANAGEMENT COMPANY LLP
280 CONGRESS STREET
BOSTON
MA
02210
0
0
1
0
Series B Preferred Stock
Common Stock
1273420
D
Series C Preferred Stock
Common Stock
451986
D
Each share of Series B Preferred Stock is convertible into one share of the Issuer's Common Stock. Upon the closing of the Issuer's initial public offering, all such shares of Series B Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 3. The Series B Preferred Stock has no expiration date.
Each share of Series C Preferred Stock is convertible into one share of the Issuer's Common Stock. Upon the closing of the Issuer's initial public offering, all such shares of Series C Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 3. The Series C Preferred Stock has no expiration date.
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. By: Wellington Management Company LLP, as Investment Advisor, /s/ Peter McIsaac, Authorized Person
2020-11-18